CoChat

Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability

Open access
Xu, Y., Bai, S.J., Lan, X.H., Qin, B., Huang, T., Xie, P. · 2016 · Brazilian Journal of Medical and Biological Research

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

New generation antidepressant therapies, including serotonin-norepinephrine reuptake inhibitor (SNRIs), were introduced in the late 1980s; however, few comprehensive studies have compared the benefits and risks of various contemporary treatments for major depressive disorder (MDD) in young patients. A comprehensive literature search of PubMed, Cochrane, Embase, Web of Science, and PsycINFO databases was conducted from 1970 to January 2015. Only clinical trials that randomly assigned one SNRI or placebo to patients aged 7 to 18 years who met the diagnostic criteria for major depressive disorder were included. Treatment success, dropout rate, and suicidal ideation/attempt outcomes were measured. Primary efficacy was determined by pooling the risk ratios (RRs) of treatment response and remission. Acceptability was determined by pooling the RRs of dropouts for all reasons and for adverse effects as well as suicide-risk outcomes. Five trials with a total of 973 patients were included. SNRIs were not significantly more effective than placebo for treatment response but were for remission. The comparison of patients taking SNRIs that dropped out for all reasons and those taking placebo did not reach statistical significance. Significantly more patients taking SNRIs dropped out for adverse effects than those taking placebo. No significant difference was found in suicide-related risk outcomes. SNRI therapy does not display a superior efficacy and is not better tolerated compared to placebo in these young patients. However, duloxetine has a potential beneficial effect for depression in young populations, showing a need for further research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1590/1414-431x20164806

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Identification process for study inclusion in the meta-analysis.
Figure 1 Identification process for study inclusion in the meta-analysis.CC BY · PubMed Central
Figure 2 Primary outcome and secondary outcome: serotonin-norepinephrine reuptake inhibitor (SNRIs) vs placebo paradigms. A, comparison of SNRIs vs placebo for the primary outcome (response at end of treatment). B, comparison of SNRIs vs placebo for the secondary outcome (remission at end of treatment). See Table 1 for details of references.
Figure 2 Primary outcome and secondary outcome: serotonin-norepinephrine reuptake inhibitor (SNRIs) vs placebo paradigms. A, comparison of SNRIs vs placebo for the primary outcome (response at end of treatment). B, comparison of SNRIs vs placebo for the secondary outcome (remission at end of treatment). See Table 1 for details of references.CC BY · PubMed Central
Figure 3 Acceptability outcomes: serotonin-norepinephrine reuptake inhibitor (SNRIs) vs placebo paradigms. A, comparison of SNRIs vs placebo for suicide-related outcome. B, comparison of SNRIs vs placebo for the outcome (patients discontinued treatment due to adverse effects). C, comparison of SNRIs vs placebo for the outcome (patients discontinued treatment due to reasons unrelated to adverse effects). See Table 1 for details of references.
Figure 3 Acceptability outcomes: serotonin-norepinephrine reuptake inhibitor (SNRIs) vs placebo paradigms. A, comparison of SNRIs vs placebo for suicide-related outcome. B, comparison of SNRIs vs placebo for the outcome (patients discontinued treatment due to adverse effects). C, comparison of SNRIs vs placebo for the outcome (patients discontinued treatment due to reasons unrelated to adverse effects). See Table 1 for details of references.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 24

Metadata

Authors
Xu, Y., Bai, S. J., Lan, X. H., Qin, B., Huang, T., & Xie, P.
Affiliations
Chongqing Medical University (CN)
Corresponding author
  • Xu, Y.
  • Bai, S.J.
  • Lan, X.H.
  • Xie, P.
Venue
Brazilian Journal of Medical and Biological Research
Published
2016
Volume
49
Issue
6
ISSN
  • 0100-879X (ISSN-L)
  • 1414-431X
OpenAlex
W2402631631
Cited by
24
References
33
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 2
FWCI
0.34
Type
journal article
Language
en
Open access
Locations
  • Brazilian Journal of Medical and Biological Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
  • Americanae (AECID Library) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
serotonin-norepinephrine reuptake inhibitors, major depressive disorder, childhood depression, adolescents, duloxetine, antidepressant efficacy, treatment discontinuation, adverse effects, suicidal ideation, placebo comparison
MeSH terms
Duloxetine Hydrochloride, Serotonin and Noradrenaline Reuptake Inhibitors, Desvenlafaxine Succinate, Venlafaxine Hydrochloride, Milnacipran, Adolescent, Antidepressive Agents, Child, Cyclopropanes, Major Depressive Disorder, Female, Humans, Male, Placebos, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability. https://app.cochat.ai/papers/10.1590/1414-431x20164806
The paper
Xu, Y., Bai, S. J., Lan, X. H., Qin, B., Huang, T., & Xie, P. (2016). Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability. Brazilian Journal of Medical and Biological Research. https://doi.org/10.1590/1414-431x20164806

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.